Biomarkers

PreclinicalBiologic

CCiusss de L'Est de l'Île de Montréal

Biomarkers is one of 9 biologic programs targeting Opioid. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OpioidTerminated

OpioidPreclinical

Terminated

Competition

Competitive Landscape

11 competitors in Opioid

#DrugCompanyPhaseTrials

Oxycontin

PProtega

Phase 3

4 2

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 3

Suboxone

Merck & Co.

Phase 3

1 4

Narcan

SScienture

Phase 1

7 5

DOVATO

GSK

Phase 3

1 6

Alfenta

Jazz Pharmaceuticals

Preclinical

1 7

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 8

Imodium

KKenvue Brands

Phase 1

1 9

Biomarkers

CCiusss de L'Est de l'Île de Montréal

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid1 trial

Correlation Between NOL Index After Stimulus and Post-operative Opioid, Pain, Pre-operative Phenotype

Terminated·CCiusss de L'Est de l'Île de Montréal·N/A·NCT03422783·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biomarkers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biomarkers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biomarkers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ciusss de L'Est de l'Île de Montréal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCiusss de L'Est de l'Île de Montréal

Biomarkers

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid1 trial

References

Drug Info

Quick Facts

Related News